Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

This is an open-label, multi-center, randomized, Phase 2 study designed to compare the
efficacy and safety of pegilodecakin in combination with pembrolizumab versus pembrolizumab
alone in participants with stage IV / metastatic wild type non-small cell lung cancer and
tumors with high expression of PD-L1 (> 50%).

Inclusion Criteria:

1. Participants must have histologically or cytologically confirmed WT NSCLC that is
stage IV / metastatic or recurrent

2. Participants with tumor tissue high expression of PD-L1 as defined by Tumor Proportion
Score (TPS) ≥ 50%

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

4. Participants with measurable disease by spiral CT or MRI per RECIST v.1.1 criteria.

5. Participants that have completed prior radiotherapy or radiosurgery at least 2 weeks
prior to randomization.

6. Participants must be naïve to therapy for the advanced stage of the disease. Previous
neoadjuvant or adjuvant therapy is allowed for participants who successfully underwent
complete radical surgery and ONLY if the last treatment was administered more than 12
months prior to the start of the trial treatment

Exclusion Criteria:

1. Participants with active central nervous system (CNS) metastases or carcinomatous
meningitis

2. Participants with any serious or uncontrolled medical disorder or active infection
with the hepatitis virus or the human immunodeficiency virus (HIV)

3. Participants with Grade 1 (NCI-CTCAE v.4.03) toxicities attributed to prior
anti-cancer therapy other than alopecia and fatigue prior to randomization

4. Participants that have received pembrolizumab

5. Participants with a history of severe hypersensitivity reactions to monoclonal
antibodies

6. Pregnant or lactating women

7. Participants receiving any investigational agent within 28 days of first
administration of trial treatment

8. Participants that have received therapy with anti-tumor vaccines or other
immunostimulatory antitumor agents

9. Participants that have received therapy with anti-PD-1, anti-PD-L1, anti-PD-L-2,
anti-CD-137, and/or anti CTLA-4 antibodies